The mechanism by which stably lowly expressed SATB2 regulates radioresistance in esophageal cancer tissues requires further investigation, and we found that among all treatments, tumor tissues in which SATB2 was silenced exhibited the lowest Ki-67 expression following radiotherapy (the Sh-SATB2+IR group) (Figure 6A). The gene discussed is SATB2; the disease is esophageal cancer.